DNTH

MKT CAP:$5B

Dianthus Therapeutics Inc.

Market Cap

$5B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$81.22+$41.54 (+104.69%)

Jun 8, 2026

52W High $95.7652W Low $16.86

Company Details

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered wit...

CEO

—

IPO Date

Sep 12, 2023

Website

dianthustx.com

Key Metrics TTM

Revenue

$1M

-79.5% YoY

Net Income

-$11M

EPS (Diluted)

Free Cash Flow

-$130M

Revenue / Share

$0.03

Gross Margin

94.3%

Operating Margin

-14318.0%

Net Margin

-847.5%

FCF Margin

-9766.8%

P/S

3660.1x

P/E

Earnings Reports

Q2 2026

Aug 6, 2026

PENDING

Q1 2026

May 5, 2026

$463.0K-60.2%

FY 2025

Mar 9, 2026

$2M-67.3%

Q4 2025

Mar 9, 2026

$284.0K-78.6%

Q3 2025

Nov 5, 2025

$396.0K-81.8%

Revenue & Profitability

Valuation

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee